What should you know about Gliadel wafers and glioblastoma?

Gliadel wafers are small biodegradable implants containing carmustine, a chemotherapy medicine. During [Brain Tumour Surgery](/treatments/surgical-oncology/brain-tumour-surgery/), a surgeon may place them in the space left after removing as much tumour as is safely possible. They gradually dissolve and expose nearby remaining tumour cells to medicine. Because the treatment is placed at the tumour site, it is different from chemotherapy given through a vein or by mouth. Suitability depends on the tumour, the operation and the surgeon's assessment; the wafers do not replace the rest of the treatment plan.

Before surgery, ask whether wafers are being considered and how they may affect wound healing or later treatment. After the operation, attend wound checks and follow instructions about medicines, activity and seizure prevention. Your team may combine local treatment with [Radiotherapy](/treatments/radiation-oncology/radiotherapy/) or other [Chemotherapy](/treatments/systemic-therapy/chemotherapy/). Keep a written list of new symptoms, including headache, nausea, seizures, confusion or changes in strength, speech or vision. Follow-up scans help the team distinguish healing changes from tumour-related changes.

After brain surgery, obtain urgent help for a seizure, loss of consciousness, a rapidly worsening headache, repeated vomiting, new weakness, trouble speaking, increasing confusion or a marked change in vision. Contact the surgical team promptly for fever, redness, discharge or opening at the wound. These signs can reflect complications that need direct assessment.

Are Gliadel wafers appropriate for my operation? Where would they be placed? What wound or neurological changes should I report? How will follow-up scans be interpreted? When would radiotherapy or further chemotherapy begin?